Anaptysbio, Inc
ANAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001370053
In the last 90 days, Anaptysbio, Inc insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $1.46B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $249.4K in total
- 1
- 13F holdersQ2 2026, +8 vs. previous quarter
- 214
- 13F valueReported value at the end of Q2 2026
- $2.03B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- –
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q4 FY2025
- $27.5M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.05M
- Shares sold short
- Change
- −341.9K
- −6.3% vs. previous
- Days to cover
- 10.79
- At average daily volume
Superinvestors holding ANAB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ANAB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Anaptysbio, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 (view filing)5:47 PM ET | Oct 1 | 1 day | Renton HollingsDirector | SSale | −5.00K | $49.87 | −$249.4K | −31.3%11.0K after | 10b5-1 |
| Apr 1, 2026 (view filing) | Mar 30 | 2 days | Schmid John P.Director | SSale | −20.6K | $56.11 | −$1.16M | −39.5%31.6K after | 3 lots |
| Mar 27, 2026 (view filing) | Mar 27 | Same day | Faga DanielPresident, CEO | SSale | −17.7K | $61.61 | −$1.09M | −3.4%496.0K after | 10 lots |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Loumeau Eric JCHIEF LEGAL OFFICER | SSale | −10.0K | $54.00 | −$540.0K | −43.8%12.8K after | 10b5-1 |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Marquet MagdaDirector | SSale | −11.0K | $48.23 | −$530.6K | −52.6%9.93K after | 2 lots |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Lizzul Paul F.Chief Medical Officer | SSale | −3.65K | $44.71 | −$163.2K | −8.0%42.1K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Faga DanielPresident, CEO | SSale | −14.3K | $44.71 | −$638.5K | −2.9%479.3K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Mulroy DennisCHIEF FINANCIAL OFFICER | SSale | −2.52K | $44.71 | −$112.4K | −10.3%21.9K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Loumeau Eric JCHIEF LEGAL OFFICER | SSale | −2.21K | $44.71 | −$98.8K | −14.7%12.8K after | |
| Jan 8, 2026 (view filing) | Jan 7 | 1 day | Lizzul Paul F.Chief Medical Officer | SSale | −2.23K | $45.11 | −$100.8K | −5.7%37.2K after |
Top 10 13F holders, Q2 2026
See all 214 holdersThe largest institutional positions in Anaptysbio, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7,880,094 | $531.9M | 26.38% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,844,049 | $124.5M | 0.00% | +162,669+9.7% | Added |
| Tang Capital Management LLC | 1,330,879 | $89.8M | 4.08% | 00.0% | Unchanged |
| State Street Corp | 1,286,194 | $86.8M | 0.00% | +293,749+29.6% | Added |
| Vanguard Capital Management LLC | 906,233 | $61.2M | 0.00% | +53,082+6.2% | Added |
| Affinity Asset Advisors, LLC | 826,109 | $55.8M | 2.73% | −113,891−12.1% | Reduced |
| Sanofi | 821,917 | $55.5M | 10.39% | 00.0% | Unchanged |
| Millennium Management LLC | 807,316 | $54.5M | 0.04% | +331,744+69.8% | Added |
| Woodline Partners LP | 717,014 | $48.4M | 0.15% | +372,758+108.3% | Added |
| 683 Capital Management, LLC | 660,000 | $44.6M | 4.10% | +35,000+5.6% | Added |
Holders of 5% or more of ANAB
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Anaptysbio, Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 6.20%1.90M shares | −2.20 ppfrom 8.40% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |
| Sirenia Capital Management LP | 13G/A | 5.00%1.49M shares | −1.70 ppfrom 6.70% | May 15, 20262 filings | Aug 14, 2026 | SEC |